Lilly Launches Higher Dose Vials of Weight-Loss Drug

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.